The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants
about
Modulation of kinase-inhibitor interactions by auxiliary protein binding: crystallography studies on Aurora A interactions with VX-680 and with TPX2AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistanceA conserved protonation-dependent switch controls drug binding in the Abl kinaseSequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potencyNew Developments in Chronic Myeloid Leukemia: Implications for TherapyChronic myeloid leukemia: reminiscences and dreamsc-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutationsSmall-molecule inhibition and activation-loop trans-phosphorylation of the IGF1 receptorCrystal structures of the Lyn protein tyrosine kinase domain in its Apo- and inhibitor-bound stateStructures of human Bruton's tyrosine kinase in active and inactive conformations suggest a mechanism of activation for TEC family kinasesDiscovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFR , Kit, and Src kinases: novel type II inhibitor of gatekeeper mutantsCrystal Structures of ABL-Related Gene (ABL2) in Complex with Imatinib, Tozasertib (VX-680), and a Type I Inhibitor of the Triazole Carbothioamide ClassConformational Control Inhibition of the BCR-ABL1 Tyrosine Kinase, Including the Gatekeeper T315I Mutant, by the Switch-Control Inhibitor DCC-2036X-ray crystal structure of bone marrow kinase in the x chromosome: a Tec family kinaseCrystal structure of the EphA4 protein tyrosine kinase domain in the apo- and dasatinib-bound stateStructural and Spectroscopic Analysis of the Kinase Inhibitor Bosutinib and an Isomer of Bosutinib Binding to the Abl Tyrosine Kinase DomainA genetically encoded 19F NMR probe for tyrosine phosphorylationFGFR1 Kinase Inhibitors: Close Regioisomers Adopt Divergent Binding Modes and Display Distinct Biophysical SignaturesCrystal structure of an SH2-kinase construct of c-Abl and effect of the SH2 domain on kinase activityCharacteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors.Allosteric interactions between the myristate- and ATP-site of the Abl kinaseMolecular Determinants Underlying Binding Specificities of the ABL Kinase Inhibitors: Combining Alanine Scanning of Binding Hot Spots with Network Analysis of Residue Interactions and CoevolutionHydrophobic Core Variations Provide a Structural Framework for Tyrosine Kinase Evolution and Functional SpecializationIdentification of Dual Natural Inhibitors for Chronic Myeloid Leukemia by Virtual Screening, Molecular Dynamics Simulation and ADMET Analysis.A Discovery Strategy for Selective Inhibitors of c-Src in Complex with the Focal Adhesion Kinase SH3/SH2-binding Region.Hierarchical modeling of activation mechanisms in the ABL and EGFR kinase domains: thermodynamic and mechanistic catalysts of kinase activation by cancer mutations.Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom?Treating adults with acute lymphocytic leukemia: new pharmacotherapy options.Abelson Kinase Inhibitors Are Potent Inhibitors of Severe Acute Respiratory Syndrome Coronavirus and Middle East Respiratory Syndrome Coronavirus Fusion.A research-inspired laboratory sequence investigating acquired drug resistance.Real-time fluorescent resonance energy transfer analysis to monitor drug resistance in chronic myelogenous leukemia.Promiscuity and the conformational rearrangement of drug-like molecules: insight from the protein data bank.Computational modeling of allosteric communication reveals organizing principles of mutation-induced signaling in ABL and EGFR kinases.The energy landscape analysis of cancer mutations in protein kinasesBCR and its mutants, the reciprocal t(9;22)-associated ABL/BCR fusion proteins, differentially regulate the cytoskeleton and cell motility.New approved dasatinib regimen available for clinical use.Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial.Treatment options for patients with chronic myeloid leukemia who are resistant to or unable to tolerate imatinibFirst-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib.Dasatinib enhances megakaryocyte differentiation but inhibits platelet formation.
P2860
Q24318313-A300C2F1-EDCA-421D-9F89-D6A5C98E9CF0Q24648017-5E38045C-52F7-4982-9F52-F1967B5DB68CQ24657421-84510F38-1867-4B56-94C2-F35E103CA8AAQ24681743-5CFCEC30-E26C-4276-97E9-A1D2A6283413Q26745669-12D2B379-740E-48AC-A37F-E26D85D6436FQ26748769-A189D89F-E932-4384-8D04-41B4BDC90C4EQ27649203-F983AEC8-6CF9-42B2-B0BC-819946668A71Q27650906-309DF37A-5071-4430-9959-7293E74C217EQ27652762-491C4ED5-6548-4E8D-ADF5-7DC15543AA09Q27658863-857DA2C5-1B86-47C8-8F2A-9F1AA94F1C57Q27660281-E7D63FFB-A2A4-4A55-8738-C2B11EA9A30BQ27667290-44AC871B-B93A-4751-B6AC-E7096D1A1597Q27667482-45CDF799-812F-4F0E-8407-9765997AA77FQ27672770-BC94178F-E48C-4F0E-B91A-9A5D16A6A005Q27675279-1B3853DB-7029-4B28-B9B7-7B075B576336Q27678454-5F008530-B3A3-47D8-A307-CC35B3530374Q27684095-E7339B03-9646-4F4B-B6C8-2309080DECFDQ27684227-3401EE0B-D6E2-4108-BFA0-AA98B42F2918Q27698513-A8C49F55-1622-4CBE-81C9-AB2E617A2DE6Q27851450-DAD525D2-2788-4DA9-8EEB-526FCBE68A1AQ28476718-43DDCE91-0873-4167-A3F8-5BB8213B3881Q28548366-F399AD0E-41C7-4C6F-BF7D-361C1A9F1DAAQ28550424-98807B95-B604-4CF1-B21D-40CDAC77AFB6Q30009113-C07AD4C7-3E75-4BC7-A377-3C9DBB5C7866Q30009284-F179BB29-C775-4C6D-9F2F-BB6FB7B0116CQ30157152-6E8BD03D-C7BD-4CAB-9240-24D2B32F4F41Q30242015-6E98499A-4B96-4428-A38B-89DBC45DF410Q30243925-B4728E96-93CF-4706-B0F2-7B8B8DEF506AQ30276258-34091FE4-125D-4DD6-802E-5F602EF897D6Q30402618-32877121-93BA-4642-A036-40CBEF450DF0Q30512706-93DDE8FC-99DE-4B29-A714-53186ECD2FE2Q30876537-4B4820E1-1560-406C-977B-0547B8DD3D3CQ31036423-3ADF79FE-3D96-4699-9E1E-2797852E63FFQ31038185-23AFE522-68C4-478C-9FFB-001E8445E6B9Q33262922-BF0228AE-DB55-4614-82AC-58437038BA45Q33383640-5EBB0CCA-D228-44B5-986D-E09CA1FA79A2Q33384766-B2E0BC02-84F0-4D2D-92E0-53F92FD0F348Q33391185-AA328CE0-AC1A-4088-86AA-0C627D781BBBQ33392977-E8C03902-69FA-4B03-AB6E-B61D2AF9D4A2Q33394424-54E58309-982C-4292-B0AF-F7042602245B
P2860
The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
The structure of Dasatinib (BM ...... imatinib-resistant ABL mutants
@ast
The structure of Dasatinib (BM ...... imatinib-resistant ABL mutants
@en
The structure of Dasatinib (BM ...... imatinib-resistant ABL mutants
@nl
type
label
The structure of Dasatinib (BM ...... imatinib-resistant ABL mutants
@ast
The structure of Dasatinib (BM ...... imatinib-resistant ABL mutants
@en
The structure of Dasatinib (BM ...... imatinib-resistant ABL mutants
@nl
prefLabel
The structure of Dasatinib (BM ...... imatinib-resistant ABL mutants
@ast
The structure of Dasatinib (BM ...... imatinib-resistant ABL mutants
@en
The structure of Dasatinib (BM ...... imatinib-resistant ABL mutants
@nl
P2093
P3181
P1433
P1476
The structure of Dasatinib (BM ...... imatinib-resistant ABL mutants
@en
P2093
Chieh Ying J Chang
Dianlin Xie
Francis Y F Lee
Herbert E Klei
Janet D Cheng
John A Newitt
John S Tokarski
Kevin Kish
Louis J Lombardo
Michael Wittekind
P304
P3181
P356
10.1158/0008-5472.CAN-05-4187
P407
P577
2006-06-01T00:00:00Z